Practical Recommendations for Glucose Measurement, Glucose Monitoring and Glucose Control in Patients with Type 1 or Type 2 Diabetes in Germany.

Competing Interests: LH is active as a consultant for various companies (e.g. Roche Diagnostics, Sanofi, Abbott) in the development of new diagnostic options. He is a shareholder and advisor at Profil – Institut für Stoffwechselforschung, Neuss, as well as ProSciento, San Diego, USA. DD received remuneration from Abbott, Dexcom, Medtronic, Novo, Roche, Senseonics and is a member of the Advisory Boards of Becton Dickinson, Roche and Senseonics. TS received remuneration from Abbott, Ascensia, Astra Zeneca/Bristol- Myers Squibb, Bayer, Berlin Chemie, Boehringer Ingelheim, Eli Lilly, Medtronic, MSD, Novartis, Novo Nordisk, and Sanofi. He is a member of the Advisory Boards of Abbott, Ascensia, Bayer Vital, Boehringer Ingelheim, Eli Lilly, Janssen, Medtronic, MSD, Novo Nordisk, and Sanofi and has received support for scientific projects from: Astra Zeneca/Bristol- Myers Squibb, Becton Dickinson, Eli Lilly, MSD, Novo Nordisk, and Sanofi. SS received remuneration from Abbott, Dexcom, Roche Diagnostics, Astra Zeneca, Novo Nordisk, MSD, and Berlin Chemie. She is a member of the Advisory Boards of Abbott, Roche Diagnostics. MN was an advisor and speaker for the following companies: Abbott, Berlin Chemie, MSD, Sanofi, Medtronic, Bayer Diagnostics, and Astra Zeneca. SvS has taken on an advisory/Advisory Board position for many companies (Abbott, Eli Lilly, Medtronic, Novo Nordisk, Roche) is active in optimizing medical aid, medicine and informative literature for children with diabetes. In the past 2 years she has received remuneration from Eli Lilly, Medtronic, Merck, Novo Nordisk, Roche and Sanofi. KL received remuneration from Bayer, BDI, Lilly Deutschland, Medtronic, Menarini/Berlin Chemie, Merck Serono, MSD SHARP & DOHME, Novo Nordisk, Roche Diabetes Care, and Sanofi. She is a member of the Advisory Boards of Roche Diabetes Care, Novo Nordisk, and Sanofi-Aventis. GF is the medical head and director of the IDT (Institut für Diabetes- Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm, Ulm (Institute for Diabetes Technology, Research and Development, Ulm University)), which performs clinical studies on medical products for diabetes therapy either of its own initiative or on behalf of various companies. GF/IDT received/receives remuneration/consultancy fees from Abbott, Ascensia, Bayer, Berlin-Chemie, Becton-Dickinson, Dexcom, LifeScan, Menarini Diagnostics, Novo Nordisk, Roche, Sanofi, Sensile and Ypsomed.